Drug intelligence / Profile preview

GF159

Development stage: Unknown
Lead developer: Sinphar Pharmaceutical
Administration: Oral

Overview

GF159 is a botanical drug candidate developed by Sinphar Pharmaceutical, derived from natural plant material. It is currently being investigated for its potential applications in brain health. As of the latest company pipeline information, GF159 is in Phase 1 clinical development, with clinical efficacy studies ongoing. While the specific botanical source and molecular targets have not been publicly disclosed, the candidate represents Sinphar's strategic focus on leveraging natural products for neurological and cognitive support.

Beyond the preview

Go deeper on GF159.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GF159.

Explore the full profile